Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMP012
- Development stage
- Phase 1
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
FMP012 is a recombinant protein-based subunit malaria vaccine candidate targeting *Plasmodium falciparum*. It is based on the cell-traversal protein for ookinetes and sporozoites (CelTOS), expressed in *E. coli*, and formulated with adjuvants such as AS01B or GLA-SE to enhance immunogenicity. The primary mechanism of action is immunostimulation to elicit an immune response against the parasite. Developed by the Walter Reed Army Institute of Research and US Army Medical Research and Materiel Command, its main indication has been for the prevention of malaria in healthy adults[1][2][3][5][7].
- Other names
- Malaria vaccine PfCelTOS WRAIRMalaria vaccine recombinant FMP012Plasmodium falciparum FMP012 vaccinePlasmodium falciparum PfCelTOS vaccinePlasmodium falciparum vaccine FMP012Recombinant FMP012 malaria vaccine
02
Targets
MHC I (MHC class I})CSP (Circumsporozoite protein)TCR-FMP012-pMHC-I (T-cell receptor recognizing FMP012-derived peptide–MHC class I complexes)MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on FMP012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FMP012.